-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 17, Huahai Pharmaceutical issued an announcement stating that the company had recently received an official letter from the US FDA that the FDA had lifted the import ban on its southern Sichuan API production base
On October 8, 2018, Huahai Pharmaceuticals disclosed that the US FDA issued an import ban on the company’s southern Sichuan API production base inspection.
November 9, 2021, the company has disclosed the "Zhejiang Huahai Pharmaceutical Co.
The above-mentioned import ban issued by the FDA mainly covers the company's southern Sichuan API production base, involving 29 API products and preparation products made from APIs produced by the southern Sichuan production base